Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
36 results about "Pre osteoblasts" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Grafting Material and Agent for Improvement in bone Quality
InactiveUS20090155216A1Trend downIncrease bone densityBiocideNervous disorderPre osteoblastsWhole body
The present invention has an object to provide a transplant material allowing systemic bone substance improvement to be realized by cell transplant. The present invention teaches to use a transplant material comprising a cell selected from the group consisting of an embryonic stem cell, a mesenchymal stem cell, an osteoblast cell, a preosteoblast, a chondrocyte and a cell having a capability of bone formation through systemic or topical administration for the improvement in bone quality.
Owner:NATIONAL UNIVERSITY
Application of oligonucleotide compound of micro-RNA (ribonucleic acid) associated with senile osteoporosis
InactiveCN106167824AFunction increaseInhibit progressMicrobiological testing/measurementPre osteoblastsSenile osteopenia
The invention discloses an application of an oligonucleotide compound of micro-RNA (ribonucleic acid) associated with senile osteoporosis. The oligonucleotide compound is used for filling in the gap of micro-RNA based oligonucleotide in application of preparing the compound for promoting osteoblast functions and inhibiting the senile osteoporosis. The technical scheme includes that the micro-RNA associated with the senile osteoporosis is obtained by screening, the oligonucleotide based on the micro-RNA associated with the senile osteoporosis is synthesized and transfected to into preosteoblast and senile osteoporosis mice bodies, results indicate that the osteoblast functions can be promoted, and the progress of the senile osteoporosis is inhibited. The prepared oligonucleotide based on the micro-RNA associated with the senile osteoporosis can inhibit the degree of the senile osteoporosis by promoting the osteoblast functions, and the gap of the micro-RNA based oligonucleotide in application of preparing the compound for promoting the osteoblast functions and inhibiting the senile osteoporosis is filled in.
Owner:NORTHWESTERN POLYTECHNICAL UNIV
shRNA sequence for suppressing mouse MACF1 gene expression and application thereof
ActiveCN104531700APrevent proliferationInhibit migrationFermentationPlant genotype modificationPre osteoblastsLentivirus
The invention discloses a shRNA sequence for suppressing mouse MACF1 gene expression and application thereof to solve the technical problem of low efficiency of mouse MACF1 gene expression suppression of the conventional shRNA sequence. The technical scheme is that the shRNA sequence for suppressing mouse MACF1 gene expression is cloned to a pGLV3 lentivirus vector to obtain a recombinant lentivirus vector containing the shRNA sequence, and the recombinant lentivirus vector is used for transfecting a mouse cell to achieve the purpose of suppressing MACF1 gene expression in the cell. The shRNA sequence can remarkably suppress the mRAN expression and protein-level expression of the MACF1 gene in a mouse preosteoblast, and suppresses the functions of proliferation, migration and differentiation of the mouse preosteoblast by suppressing the expression of the MACF1 in the mouse preosteoblast. The shRNA sequence reaches a protein-level suppression ratio above 90% and the gene-level suppression ratio of 81%.
Owner:NORTHWESTERN POLYTECHNICAL UNIV
Nanoparticle-based scaffolds and implants, methods for making the same, and applications thereof
ActiveUS20140287018A1Reducing and eliminating microbial infectionEliminate and reduce sourceBiocideDental implantsAntibacterial activityAlloy
Implant-associated bacterial infections are one of the most serious complications in orthopedic surgery. Treatment of these infections often requires multiple operations, device removal, long-term systemic antibiotics, and extended rehabilitation, and is frequently ineffective, leading to worse clinical outcomes and increased financial costs. Silver nanoparticle / poly(DL-lactic-co-glycolic acid) (PLGA)-coated stainless steel alloy (SNPSA) was evaluated as a potential antimicrobial implant material. It was found that SNPSA exhibited strong antibacterial activity in vitro and ex vivo, and promoted MC3T3-E1 pre-osteoblasts proliferation and maturation in vitro. Furthermore, SNPSA implants induced osteogenesis while suppressing bacterial survival in contaminated rat femoral canals. The results indicate that SNPSA has simultaneous antimicrobial and osteoinductive properties that make it a promising therapeutic material in orthopedic surgery.
Owner:RGT UNIV OF CALIFORNIA
Application of miR-489-3p to preparation of medicines for diagnosing and treating human osteoporosis
The invention discloses application of miR-489-3p to preparation of medicines for diagnosing and treating human osteoporosis. According to the technical scheme, the detection of thighbone tissue samples of elderly patients with osteoporosis shows that miR-489-3p is low in expression in human osteoporosis tissue samples and can be used as a marker gene for diagnosing osteoporosis; an analogue and an antagonist of miR-489-3p are designed and prepared, then the analogue and the antagonist of the miR-489-3p are transfected into mice pre-osteoblasts MC3T3-E1 for carrying out a mineralization-alizarin red s dyeing experiment and an ALP dyeing experiment; technical detection of qPCR and Western blot shows that miR-489-3p can accelerate osteocyte differentiation and also can carry out targeted regulation on non-receptor protein-tyrosine-phosphatase6 (PTPN6) molecules. The application of miR-489-3p to preparation of medicines for diagnosing and treating human osteoporosis shows that miR-489-3p can regulate PTPN6 molecules to be used as target sites of action of medicines for treating skeleton system diseases such as osteoporosis.
Owner:NORTHWESTERN POLYTECHNICAL UNIV
Gene expression associated with osteobla st differentiation
The present invention identifies genes whose expression pattern is altered when pre-osteoblastic cells undergo differentiation into mature osteoblasts. The genes identified may be used as markers for the differentiation process. The present invention also provides methods to screen agents that are capable of modulating the differentiation process. The present invention also provides methods of identifying therapeutic agents that stimulate bone formation by analyzing the expression of one or more of the genes identified.
Owner:SUSA SPRING MIRA +1
Preparation method for facilitation bone titanium tantalum composite
InactiveCN110306073ADoes not affect proliferationPromote osteogenic differentiationTissue regenerationProsthesisPre osteoblastsRubidium
The invention discloses a preparation method for a facilitation bone titanium tantalum composite. According to the technical scheme, titanium powder and tantalum powder are subjected to ball milling and mixing, then discharge plasma sintering is conducted, polishing is conducted, and the facilitation bone titanium tantalum composite is obtained, has biocompatibility, does not have cytotoxicity, does not influence cell proliferation, and has good induction effect on osteogenic differentiation of preosteoblasts; and meanwhile alkali-heat-treatment is conducted on the titanium tantalum composite,rubidium is mixed into the surface of the titanium tantalum composite, bioactivity of the titanium tantalum composite can be further promoted, and the preosteoblasts are further facilitated and induced to differentiate to osteoblasts. If before alkali-heat-treatment, sand blasting treatment and acid treatment are conducted first, facilitation bone ability of the obtained facilitation bone titanium tantalum composite is more excellent.
Owner:CENT SOUTH UNIV
Osteoblast factor(s) that regulates human prostate cancer migration to and invasion of bone
InactiveUS20060008858A1Immunoglobulins against cytokines/lymphokines/interferonsImmunoglobulins against growth factorsProstate cancer cellLymphatic Spread
Human osteogenic cells secrete biological activities that stimulate cancer cells to migrate to and / or invade tissues. Conditioned medium (CM) produced by human pre-osteoblasts and osteoblasts induced migration and tissue invasion of human prostate cancer cells. Thus, conditioned media and / or proteins isolated therefrom may be used to identify metastasis-inducing factors. Also described are methods of identifying an inhibitor of such factors.
Owner:RGT UNIV OF MICHIGAN
Surface rubidium-doped titanium material as well as preparation method and application thereof
ActiveCN109589449AGood biocompatibilitySolve problems such as wound infectionTissue regenerationCoatingsLithiumPre osteoblasts
The invention relates to a surface rubidium-doped titanium material as well as a preparation method and application thereof. The preparation method comprises the following steps: cleaning a titanium material after alkali hot treatment to be neutral, drying, then soaking in a rubidium salt solution for reaction and obtaining a titanium material after rubidium salt treatment; calcining the titaniummaterial after rubidium salt treatment at a temperature of 500-750 DEG C to obtain the surface rubidium-doped titanium material; in the rubidium salt solution, the concentration of rubidium ions is 1-10 mol / L. The surface rubidium-doped titanium material provided by the invention has a staphylococcus aureus growth resistance function, is good in biocompatibility and free from cytotoxicity, does not affect the cell proliferation and has a good effect on inducing osteoblastic differentiation of preosteoblasts. The material has antibacterial property and biocompatibility and can effectively solvewound infection and other problems when the titanium material is clinically applied, thereby having a wide application prospect in clinical bone repair.
Owner:CENT SOUTH UNIV
VEGF-165 activator and use thereof for promoting stem cell differentiation
ActiveCN108913657APromote differentiationSkeletal/connective tissue cellsCell culture active agentsCalcificationBone formation
The present invention relates to a VEGF-165 activator and use thereof for promoting stem cell differentiation. Alkaline phosphatase (ALP) is an early osteogenesis marker, and is mainly distributed incell membranes to promote cell calcification. The quantitative detection of the ALP can reflect the differentiation level of osteoblasts. If the activity of the ALP is higher, the higher activity of the ALP indicates that pre-osteoblasts have more obvious differentiation tendency to mature osteoblasts. The high expression of the activity of the ALP is an early marker of osteoblast differentiationand maturation. When the activity of the ALP is enhanced, bone formation is enhanced, and bone matrix mineralization is promoted. Therefore, the activity of the ALP is a good indicator for reflectingthe degree differentiation and the functional status of the osteoblasts. The osteogenic differentiation of hBMSCs can be promoted by activating BMP-2 protein expression in the hBMSCs by to-be-tested compounds 1 to 3. The osteogenic differentiation of the hBMSCs can be promoted by activating VEGF-165 protein expression in the hBMSCs by to-be-tested compounds 4 and 5.
Owner:ASIA REGENERATIVE MEDICINE LTD
Antibacterial osteogenesis-promoting rubidium titanium tantalum composite material and preparation method and application thereof
ActiveCN110201237AGood biocompatibilitySolve problems such as poor biocompatibilityTissue regenerationProsthesisRubidiumCytotoxicity
The invention discloses an antibacterial osteogenesis-promoting rubidium titanium tantalum composite material and a preparation method thereof. The preparation method includes: performing sand blasting, acid treatment and alkali-heat treatment on a titanium tantalum composite material synthesized by cold isostatic pressing and vacuum sintering to modify the surface of the titanium tantalum composite material, doping rubidium salt into the surface of the titanium tantalum composite material after surface modifying through ion exchange, and sintering at high temperature to obtain the antibacterial osteogenesis-promoting rubidium titanium tantalum composite material. The rubidium titanium tantalum composite material has good antibacterial performance and biocompatibility, is free of cytotoxicity, can promote cell proliferation, has good effect of inducing preosteoblast osteogenesis differentiation, can effectively solve the problems that bone repair materials are prone to being affected with bacteria during clinical application and an implanted material is poor in compatibility with human body and has wide application prospect in clinical bone repair.
Owner:CENT SOUTH UNIV
BMP-2 activator and application of same in stem cell induced differentiation
ActiveCN109055307ASkeletal/connective tissue cellsCell culture active agentsPre osteoblastsBone formation
The invention relates to a BMP-2 activator and application of the same in stem cell induced differentiation. Alkaline phosphatases (ALPs), early osteogenesis markers, are mainly distributed in cytomembranes to promote cell calcification, quantitative detection of the ALPs can reflect the differentiation level of osteoblasts, and the higher the activity is, the more obvious differentiation of preosteoblasts into the mature osteoblasts is; the high expression of the ALP activity is an early indicator for osteogenic differentiation maturation, bone formation is enhanced when the ALP activity is improved, and bone matrix mineralization is promoted, so that the ALP activity is a good indicator reflecting the differentiation degree and the functional status of the osteoblasts; to-be-tested compounds 1-3 promote osteogenic differentiation of hBMSCs by activating BMP-2 protein expression in the hBMSCs, and to-be-tested compounds 4 and 5 promote osteogenic differentiation of the hBMSCs by activating VEGF165 protein expression in the hBMSCs.
Owner:杭州爱唯生命科技有限公司
Pharmaceutical composition for treatment of bone-related disease
ActiveUS11253498B2Preventing or treating a bone-related diseasePromote differentiationSkeletal disorderAmide active ingredientsBone marrow cellOsteocyte
The present invention relates to a pharmaceutical composition for preventing or treating a bone-related disease; and the pharmaceutical composition is very effective in preventing or treating bone-related diseases in that it not only promotes differentiation of preosteoblast cells into osteoblasts to induce production of mineralized nodules, but also, at the same time, inhibits differentiation of bone marrow cells into osteoclasts and the function of osteoclasts so that bone homeostasis is effectively regulated. In addition, the present invention relates to a pharmaceutical composition for preventing or treating a menopausal disease, in particular, a menopausal bone disease; and the pharmaceutical composition is very effective in preventing or treating a menopausal bone-related disease in that it not only increases the volume of trabecular bone and promotes differentiation of preosteoblast cells into osteoblasts to induce production of mineralized nodules, but also, at the same time, inhibits differentiation of bone marrow cells into osteoclasts and the function of osteoclasts so that bone homeostasis is effectively regulated.
Owner:NEXYON BIOTECH CO LTD
Osteogenesis promoting rubidium-titanium-tantalum-containing composite material, preparation method thereof and application of composite material
ActiveCN110201222AGood bone formationOsteogenic propertiesPharmaceutical delivery mechanismTissue regenerationOsteoblastRubidium
The invention discloses an osteogenesis promoting rubidium-titanium-tantalum-containing composite material, a preparation method thereof and an application of the composite material. According to themethod, sand blasting, acid treatment and alkali heat treatment of a titanium tantalum composite material synthesized by plasma activated sintering are implemented, so that the surface of the titaniumtantalum composite material is modified, rubidium salt penetrates the titanium tantalum composite material with the modified surface through ion exchange, and the material is calcined at high temperature to prepare the osteogenesis promoting rubidium-titanium-tantalum-containing composite material. The composite material has good biocompatibility, does not have cytotoxicity, facilitates cell proliferation and effectively induces pre-osteoblasts to achieve osteoblast differentiation. The material can effectively solve the problems of poor compatibility of bone repairing materials and a human body when the bone repairing materials are clinically applied and the like, and the material has a wide application prospect in clinical bone repairing.
Owner:CENT SOUTH UNIV
Immortalized preosteoblasts and method for their production
The present invention relates to novel immortalized pre-osteoblast cell lines derived from the periost and capable of differentiate to osteoblasts. In particular, the present invention pertains to the use of such cell lines in assays for detecting substances controlling the differentiation of pre-osteoblasts to osteoblasts and for detecting substances enabling improved bone formation, maintenance of bone mass, bone repair and for preventing the onset of osteoporosis.
Owner:NESTEC SA
Vascular endothelial growth factor 165 activators and application of same to stem cells
ActiveCN109022354ASkeletal/connective tissue cellsCell culture active agentsBone formationCell membrane
The invention relates to vascular endothelial growth factor 165 activators and application of the same to stem cells. Alkaline phosphatase (ALP) is an early osteogenesis marker, is mainly distributedin cell membranes and can promote cell calcification. Quantitative detection of ALP can reflect the differentiation level of osteoblasts. The higher the activity of ALP is, the more obvious the differentiation of preosteoblasts into mature osteoblasts is. The high expression of ALP activity is an early indicator for the differentiation and maturation of osteoblasts. When ALP activity is enhanced,bone formation is improved and bone matrix mineralization formation is promoted. Therefore, ALP activity is a good indicator reflecting the differentiation degree and functional status of osteoblasts.To-be-tested compounds 1 to 3 promote the osteogenic differentiation of hBMSCs by activating BMP-2 protein expression in hBMSCs; and to-be-tested compounds 4 and 5 promote the osteogenic differentiation of hBMSCs by activating VEGF-165 protein expression in hBMSCs.
Owner:广东创晟控股集团有限公司
Shrna sequence and application thereof for inhibiting expression of mouse macf1 gene
ActiveCN104531700BImprove efficiencyFermentationPlant genotype modificationLentivirusPre osteoblasts
The invention discloses an shRNA sequence for inhibiting mouse MACF1 gene expression and application thereof, which is used to solve the technical problem of low efficiency of the existing shRNA sequence for inhibiting mouse MACF1 gene expression. The technical solution is to clone the shRNA sequence that inhibits the expression of the mouse MACF1 gene into the pGLV3 lentiviral vector to obtain a recombinant lentiviral vector containing the shRNA sequence; the obtained recombinant vector is used to transfect mouse cells to achieve inhibition Purpose of MACF1 gene expression in cells. The shRNA sequence mentioned above can obviously inhibit the expression of MACF1 gene at mRNA and protein levels in mouse preosteoblasts. The proliferation, migration and differentiation functions of preosteoblasts were inhibited by inhibiting the expression of MACF1 in mouse preosteoblasts. The inhibition rate of the present invention at the protein level reaches over 90%, and the inhibition rate at the gene level reaches 81%.
Owner:NORTHWESTERN POLYTECHNICAL UNIV
A kind of activator of vascular endothelial growth factor 165 and its application in stem cells
ActiveCN109022354BSkeletal/connective tissue cellsCell culture active agentsCell membraneOsteoblast cell differentiation
The invention relates to a vascular endothelial growth factor 165 activator and its application in stem cells. Alkaline phosphatase (ALP) is a marker of early osteogenesis, which is mainly distributed in the cell membrane and promotes cell calcification. The quantitative detection of ALP can reflect the differentiation level of osteoblasts. Cell differentiation is more obvious. High expression of ALP activity is an early marker of osteoblast differentiation and maturation. When ALP activity is enhanced, bone formation is enhanced and bone matrix mineralization is promoted. Therefore, ALP activity is a good indicator to reflect the degree of differentiation and functional status of osteoblasts. Test compounds 1-3 promote the osteogenic differentiation of hBMSCs by activating the expression of BMP-2 protein in hBMSCs, and test compounds 4 and 5 promote the osteogenic differentiation of hBMSCs by activating the expression of VEGF-165 protein in hBMSCs.
Owner:广东创晟控股集团有限公司
A kind of composite material containing rubidium, titanium and tantalum for bone formation and its preparation method and application
ActiveCN110201222BGood bone formationOsteogenic propertiesPharmaceutical delivery mechanismTissue regenerationOsteoblastBone formation
The invention discloses a bone-promoting rubidium-titanium-tantalum composite material and its preparation method and application. The method performs sand blasting, acid treatment and alkali heat treatment on the titanium-tantalum composite material synthesized by plasma activation and sintering to modify the surface of the titanium-tantalum composite material. properties, and the surface of the surface-modified titanium-tantalum composite material is doped with rubidium salt through ion exchange, and finally the bone-promoting rubidium-titanium-tantalum composite material is prepared by high-temperature calcination. The material of the invention has good biocompatibility, does not have cytotoxicity, promotes cell proliferation, and has a good effect of inducing osteogenic differentiation of pre-osteoblasts. The material can effectively solve the problems of poor compatibility with the human body in clinical application of bone repair materials, and has broad application prospects in clinical bone repair.
Owner:CENT SOUTH UNIV
Pharmaceutical Composition for Prevention or Treatment of Bone-Related Disease
ActiveUS20200188353A1Promote differentiationInhibition of differentiationSkeletal disorderAmide active ingredientsDiseaseBone marrow cell
The present invention relates to a pharmaceutical composition for preventing or treating a bone-related disease; and the pharmaceutical composition is very effective in preventing or treating bone-related diseases in that it not only promotes differentiation of preosteoblast cells into osteoblasts to induce production of mineralized nodules, but also, at the same time, inhibits differentiation of bone marrow cells into osteoclasts and the function of osteoclasts so that bone homeostasis is effectively regulated. In addition, the present invention relates to a pharmaceutical composition for preventing or treating a menopausal disease, in particular, a menopausal bone disease; and the pharmaceutical composition is very effective in preventing or treating a menopausal bone-related disease in that it not only increases the volume of trabecular bone and promotes differentiation of preosteoblast cells into osteoblasts to induce production of mineralized nodules, but also, at the same time, inhibits differentiation of bone marrow cells into osteoclasts and the function of osteoclasts so that bone homeostasis is effectively regulated.
Owner:NEXYON BIOTECH COL LTD
Multifunctional titanium alloy coating and preparation method and application thereof
PendingCN114481264AImprove antibacterial propertiesPracticalElectrophoretic coatingsTissue regenerationTitanium metalSurgical implant
The invention discloses a multifunctional titanium alloy coating and a preparation method and application thereof. The preparation method comprises the following steps: depositing graphene (GO) and berberine on the surface of a pure titanium metal sheet by adopting a cathode electrophoretic deposition technology to prepare a titanium alloy coating Beramp; gO (at) Ti has no obvious cytotoxicity, and an in-vitro osteogenesis activity evaluation result shows that compared with a Ti group, Beramp, GO (at) Ti and GO (at) Ti have no obvious cytotoxicity; and the preosteoblasts on the GO (at) Ti group show higher expression of osteogenesis-related genes. Meanwhile, bacterial proliferation and plate coating results show that Beramp; and the GO (at) Ti group has excellent antibacterial performance through the synergistic effect of GO and berberine. In-vitro experiments also show that the material has good antibacterial effect and biocompatibility, and shows huge potential in surgical implants.
Owner:SHANGHAI FIRST PEOPLES HOSPITAL
A bone morphogenetic protein 2 activator and its application in promoting osteogenic differentiation of mesenchymal stem cells
ActiveCN109022353BSkeletal/connective tissue cellsCell culture active agentsOsseous DifferentiationOsteocyte
Owner:SHANDONG XINRUI BIOTECH CO LTD
Metal support filled with magnetic composite material and preparation method of metal support
PendingCN114504681APromote new lifeStimulate depositionAdditive manufacturing apparatusTissue regenerationCell-Extracellular MatrixBlood vessel
The invention discloses a metal stent filled with a magnetic composite material, the metal stent is composed of a magnetic composite material and a three-dimensional porous metal stent, the magnetic composite material is formed by nano magnetic particles, gelatin and hydroxyapatite powder, and the metal stent is filled with the magnetic composite material. The mass ratio of the hydroxyapatite powder to the gelatin to the nano magnetic particles in the magnetic composite material is 1: 1: (0.1-1). According to the invention, two bone matrix main components (collagen and nano-hydroxyapatite) are adopted, and a degradable bionic three-dimensional micro-scaffold is built in each hole of porous titanium; meanwhile, nano magnetic particles and a static magnetic field are introduced to promote angiogenesis and stimulate differentiation of preosteoblasts to osteoblasts and deposition of extracellular matrixes, so that an optimal proliferation and differentiation environment is provided for bone formation related cells.
Owner:PEKING UNION MEDICAL COLLEGE HOSPITAL CHINESE ACAD OF MEDICAL SCI
Bone morphogenetic protein 2 activators and application of same to promotion of osteogenic differentiation of mesenchymal stem cells
ActiveCN109022353ASkeletal/connective tissue cellsCell culture active agentsBone formationCalcification
The invention relates to bone morphogenetic protein 2 activators and application of the same to promotion of the osteogenic differentiation of mesenchymal stem cells. Alkaline phosphatase (ALP) is anearly osteogenesis marker, is mainly distributed in cell membranes and can promote cell calcification. Quantitative detection of ALP can reflect the differentiation level of osteoblasts. The higher the activity of ALP is, the more obvious the differentiation of preosteoblasts into mature osteoblasts is. The high expression of ALP activity is an early indicator for the differentiation and maturation of osteoblasts. When ALP activity is enhanced, bone formation is improved and bone matrix mineralization formation is promoted. Therefore, ALP activity is a good indicator reflecting the differentiation degree and functional status of osteoblasts. To-be-tested compounds 1 to 3 promote the osteogenic differentiation of hBMSCs by activating BMP-2 protein expression in hBMSCs; and to-be-tested compounds 4 and 5 promote the osteogenic differentiation of hBMSCs by activating VEGF165 protein expression in hBMSCs.
Owner:SHANDONG XINRUI BIOTECH CO LTD
Bone morphogenetic protein 2 activator for inducing directed differentiation of stem cells
ActiveCN108913658ASkeletal/connective tissue cellsCell culture active agentsCell membraneCalcification
The present invention relates to a bone morphogenetic protein 2 activator for promoting directed differentiation of stem cells. Alkaline phosphatase (ALP) is an early osteogenesis marker, and is mainly distributed in cell membranes to promote cell calcification. The quantitative detection of the ALP can reflect the differentiation level of osteoblasts. If the activity of the ALP is higher, the higher activity of the ALP indicates that pre-osteoblasts have more obvious differentiation tendency to mature osteoblasts. The high expression of the activity of the ALP is an early marker of osteoblastdifferentiation and maturation. When the activity of the ALP is enhanced, bone formation is enhanced, and bone matrix mineralization is promoted. Therefore, the activity of the ALP is a good indicator for reflecting the degree differentiation and the functional status of the osteoblasts. The osteogenic differentiation of hBMSCs can be promoted by activating BMP-2 protein expression in the hBMSCsby to-be-tested compounds 1 to 3. The osteogenic differentiation of the hBMSCs can be promoted by activating VEGF-165 protein expression in the hBMSCs by to-be-tested compounds 4 and 5.
Owner:广东创晟控股集团有限公司
A kind of vegf-165 activator and its application for promoting stem cell differentiation
ActiveCN108913657BPromote differentiationSkeletal/connective tissue cellsCell culture active agentsPre osteoblastsCell membrane
The invention relates to a VEGF-165 activator and its use for promoting stem cell differentiation. Alkaline phosphatase (ALP) is a marker of early osteogenesis, which is mainly distributed in the cell membrane and promotes cell calcification. The quantitative detection of ALP can reflect the differentiation level of osteoblasts. Cell differentiation is more obvious. High expression of ALP activity is an early marker of osteoblast differentiation and maturation. When ALP activity is enhanced, bone formation is enhanced and bone matrix mineralization is promoted. Therefore, ALP activity is a good indicator to reflect the degree of differentiation and functional status of osteoblasts. Test compounds 1-3 promote the osteogenic differentiation of hBMSCs by activating the expression of BMP-2 protein in hBMSCs, and test compounds 4 and 5 promote the osteogenic differentiation of hBMSCs by activating the expression of VEGF-165 protein in hBMSCs.
Owner:ASIA REGENERATIVE MEDICINE LTD
Application of hippuric acid in preparing osteoporosis resistant drug
InactiveCN109364057APromote formationIncrease the number ofOrganic active ingredientsSkeletal disorderMedicineC2C12
The invention discloses an application of hippuric acid in preparing an osteoporosis resistant drug. The structure of the hippuric acid is shown in a formula (I). The hippuric acid can promote proliferation and differentiation of marrow ST2 matrix cells (ST2 Cells), double potential preosteoblasts (C2C12 Cells) and primary mouse marrow stroma cells (BMC) to form osteoblasts, inhibit proliferationof preadipocytes (3T3L1) and promote conversion thereof into osteoblasts, promote formation of bone trabecula in vivo, increase the quantity of osteoblasts, reduce the quantity of osteoclasts, improvethe mineralization rate of surface of the bone and the bone speed of formation and increase the bone weight, promote expression of p38 MAP kinase and osterix pathway proteins and enhance related mRNAlevel, inhibit expression of PPARgamma proteins and reduce the level of mRNA and treat osteoporosis by increasing the bone weight.
Owner:浙江欧谱生物科技有限公司
An antibacterial bone-containing rubidium-titanium-tantalum composite material and its preparation method and application
ActiveCN110201237BImprove antibacterial propertiesHigh dopingTissue regenerationProsthesisIon exchangeCytotoxicity
The invention discloses an antibacterial and bone-containing rubidium-titanium-tantalum composite material and a preparation method thereof. In the method, the titanium-tantalum composite material synthesized by cold isostatic pressing and vacuum sintering is subjected to sandblasting, acid treatment and alkali heat treatment to make titanium-tantalum composite The surface of the material is modified, and the surface of the surface-modified titanium-tantalum composite material is doped with rubidium salt through ion exchange, and finally the antibacterial bone-promoting rubidium-titanium-tantalum composite material is prepared by high-temperature calcination. The material of the invention has good antibacterial properties and biocompatibility, does not have cytotoxicity, promotes cell proliferation, and has a good effect of inducing osteogenic differentiation of pre-osteoblasts. The material can effectively solve the problems of easy infection of bacteria in clinical application of bone repair materials and poor compatibility between implant materials and human body, and has broad application prospects in clinical bone repair.
Owner:CENT SOUTH UNIV
A kind of application of aralia saponin ⅳ
ActiveCN108685930BPromote growthPromotes the formation of mineralized nodulesOrganic active ingredientsSkeletal disorderDiseasePre osteoblasts
Owner:MINZU UNIVERSITY OF CHINA
Method for inducing bone mesenchymal stem cells to osteoblast differentiation
InactiveCN106893693ARaise the ratioReduce riskCell culture supports/coatingSkeletal/connective tissue cellsStrontium titanateUltraviolet lights
The invention discloses a method for inducing bone mesenchymal stem cells to osteoblast differentiation. A crystal face single crystal surface of strontium titanate {100} is irradiated with ultraviolet light firstly to produce a surface with specific hydroxyl properties, then bone mesenchymal stem cells are cultured on the surface, preosteoblasts can be obtained after the culturing for 7 days by using the conventional DMEM basal medium, and mature differentiation osteoblasts can be obtained after the culturing for 14 days. The method for inducing directional differentiation of the stem cells by utilizing hydroxyl properties of the material surface, provided by the invention, is simple and convenient to operate and very low in cost, can obviously improve the differentiation ratio of the mesenchymal stem cells into the osteoblasts, and further can avoid application risks and immunogenicity of animal serums and biochemical reagents, thereby being applicable to the fields of bone tissue repair, reconstruction and the like.
Owner:周婧
Features
- R&D
- Intellectual Property
- Life Sciences
- Materials
- Tech Scout
Why Patsnap Eureka
- Unparalleled Data Quality
- Higher Quality Content
- 60% Fewer Hallucinations
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2025 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com